SciSparc
and Clearmind Medicine Inc. Collaboration Yields Positive Results
for its Psychedelic Combination Treatment
Pre-clinical
trials based on the proprietary combination demonstrate significant
suppressive effect on alcohol consumption
TEL AVIV, Israel, May 24,
2022 -- InvestorsHub NewsWire -- SciSparc Ltd. (NASDAQ:
SPRC), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to
treat disorders of the central nervous system (the "Company" or
"SciSparc"), today announced positive safety profile results from
its joint pre-clinical trial with Clearmind Medicine Inc.
("Clearmind") (CSE:
CMND), (OTC:
CMNDF), (FSE: CWY0), a psychedelic pharmaceutical company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems. The trial tested the proprietary
combination of SciSparc's CannAmide™ with Clearmind's psychedelic
molecule, MEAI, for alcohol consumption.
A histopathology
assessment was conducted on several organs (heart, lungs, liver,
kidneys, brain, pancreas, spleen, and thyroid gland) from all
experiment groups (n=3-5 per group) to determine the safety of the
proprietary combination of MEAI and CannAmide™ versus control
(mice) that were not exposed to alcohol). The severity of changes
was scored by a 5-point scale by a qualified blinded toxicologist
(Schafer et al., Toxicol Pathol 2018, 46:256-265). The results
indicated a high safety profile of the combination treatment with
no treatment-related changes observed.
Oz Adler,
SciSparc's Chief Executive Officer, commented, "We are pleased with
these latest results that confirm the high safety profile of the
psychedelic combination treatment. Previous testing results showed
high efficacy potential in treating alcoholism when using this
combination. We plan on further exploring the safety and
efficacy of combining our technology with Clearmind's
novel molecule."
Previously announced
successful results showed a significant dose dependent effect for
the MEAI treatment in reducing alcohol consumption in treated
animals, with additional significant effect when combining
CannAmide™ with the lower sub-effective MEAI
dose.
Results showed that alcohol
consumption was significantly reduced following treatment with MEAI
at a dose of 40 mg/kg and higher (p<0.01) compared to
consumption before treatment. Alcohol consumption was significantly
reduced following dual treatment with 25 mg/kg CannAmide™ in
addition to MEAI at a dose of 20 mg/kg compared to consumption
before treatment. The mice were provided with 20% alcohol solution
for 24 hours, three times a week, for seven weeks, and were treated
every day with MEAI or MEAI/CannAmide™ during the last two weeks of
alcohol treatment. The alcohol consumption was measured by weighing
the alcohol bottles before and after; water consumption was
measured similarly in parallel.
About
SciSparc (NASDAQ: SPRC):
SciSparc Ltd. is a specialty
clinical-stage pharmaceutical company led by an experienced team of
senior executives and scientists. SciSparc's focus is on creating
and enhancing a portfolio of technologies and assets based on
cannabinoid pharmaceuticals. With this focus, the Company is
currently engaged in the following drug development programs based
on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the
treatment of Tourette syndrome, for the treatment of Alzheimer's
disease and agitation; SCI-160 for the treatment of pain; and
SCI-210 for the treatment of autism spectrum disorder and status
epilepticus.
About
Clearmind Medicine
Clearmind Medicine is a new biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder, binge
eating and depression.
The Israeli-Canadian
company holds several patents for the non-hallucinogenic compound
MEAI. The company intends to seek additional patents for its
compounds whenever warranted and will remain opportunistic
regarding the acquisition of additional intellectual property to
build its portfolio.
Shares of Clearmind
are listed for trading on the Canadian Securities Exchange under
the symbol "CMND", the Frankfurt Stock Exchange under the symbol
"CWYO" and on the OTC pink under the symbol "CMNDF".
Forward-Looking
Statements:
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995
and other Federal securities laws. For example, SciSparc is using
forward-looking statements when it discusses the potential benefits
of MEAI treatment and its potential in reducing alcohol consumption
of the treated animals, with additional significant effect for the
CannAmide™ treatment at the lower sub-effective MEAI dose, and its
plans to further explore the safety and efficacy of combining MEAI
and CannAmide™. Historic results of scientific research and
clinical and preclinical trials do not guarantee that the
conclusions of future research or trials will suggest identical or
even similar conclusions. Because such statements deal with future
events and are based on SciSparc's current expectations, they are
subject to various risks and uncertainties and actual results,
performance or achievements of SciSparc could differ materially
from those described in or implied by the statements in this press
release. The forward-looking statements contained or implied in
this press release are subject to other risks and uncertainties,
including those discussed under the heading "Risk Factors" in
SciSparc's Annual Report on Form 20-F filed with the SEC
on April [28], 2022 ,
and in subsequent filings with the U.S. Securities and Exchange
Commission. Except as otherwise required by law, SciSparc disclaims
any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
Investor
Contact:
IR@scisparc.com
Tel:
+972-3-6167055